DBV Technologies - Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 03/31/2024 | 96,434,369 | Total gross of voting rights: 96,434,369 |
| Total net* of voting rights: 96,171,725 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$10.83 |
| Daily Change: | -0.16 -1.46 |
| Daily Volume: | 2,574 |
| Market Cap: | US$296.310M |
January 08, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
